Tenofovir Gel Overview: CONRAD

Tenofovir Gel Overview: CONRAD

People with herpes gladiatorum can have periods where the virus is inactive and cannot be spread to others. Sixty-one sexually active women aged 18–24 years were recruited from three sites in the United States. I had some symptoms from back then though, that I wanted you to comment on nonetheless. In 2010, researchers at the Centre for the AIDS Programme of Research in South Africa (CAPRISA) completed a study (CAPRISA 004) of 889 women who inserted tenofovir gel in their vaginas before and after sex, and found that it was 39% effective in reducing a woman’s risk of becoming infected with HIV and 51% effective in preventing genital herpes infections. From the very first time you get a HSV infection (main infection), the virus remains in your body for the rest of your life but remains largely inactive (dormant). No serious AEs or withdrawals due to AEs were reported. I fear ‘what ifs’ that this may have been herpes and I will never know… I do not recall having any spots on my hands or fingers though… so would that help my case that it wasnt herpes?
Tenofovir Gel Overview: CONRAD

Adherence in all arms of the study was too low to confirm effectiveness. After you have the primary infection, whether or not you have symptoms, the virus lies inactive in your body but can become active from time to time. Exposure to VivaGel and VivaGel placebo resulted in minor shifts in the vaginal microflora but there was no overall impact on incidence of bacterial vaginosis as assessed by Nugent score. Any chance those rashes could be have been herpetic eczema, or is that a more severe thing? Overall, out of 2059 enrolled participants, a total of 123 HIV infections occurred, with 61 in the TFV arm and 62 in the placebo group (Rees et al., 2015). Sometimes, if the infection is specifically severe or frequent, your Doctor might prescribe anti-viral tablets. SPL7013 Gel, or VivaGel®, is a dendrimer-based topical microbicide candidate currently being developed to prevent STIs and as a treatment for bacterial vaginosis.

A case-cohort analysis of 214 participants in the TFV-treated group showed that detection of TFV in genital fluids was significantly associated with a 52% reduction in HIV acquisition. In the same analysis, women who did not use the gel at all (no drug detected in genital samples) were significantly more likely to become infected. We have looked at a large number of these programs and selected a small number that we feel have something significant to offer someone trying to cope with herpes. Data from the first two studies indicate that 3% VivaGel is safe and well tolerated when administered to the vaginal [6] or penile epithelium [7] for up to seven days.

You may also like